"Osteosarcoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
Descriptor ID |
D012516
|
MeSH Number(s) |
C04.557.450.565.575.650 C04.557.450.795.620
|
Concept/Terms |
Osteosarcoma- Osteosarcoma
- Osteosarcomas
- Osteosarcoma Tumor
- Osteosarcoma Tumors
- Tumor, Osteosarcoma
- Tumors, Osteosarcoma
- Sarcoma, Osteogenic
- Osteogenic Sarcomas
- Sarcomas, Osteogenic
- Osteogenic Sarcoma
|
Below are MeSH descriptors whose meaning is more general than "Osteosarcoma".
Below are MeSH descriptors whose meaning is more specific than "Osteosarcoma".
This graph shows the total number of publications written about "Osteosarcoma" by people in this website by year, and whether "Osteosarcoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 4 | 4 | 8 |
1995 | 10 | 5 | 15 |
1996 | 6 | 3 | 9 |
1997 | 6 | 3 | 9 |
1998 | 2 | 5 | 7 |
1999 | 4 | 3 | 7 |
2000 | 6 | 3 | 9 |
2001 | 7 | 2 | 9 |
2002 | 8 | 3 | 11 |
2003 | 13 | 6 | 19 |
2004 | 19 | 3 | 22 |
2005 | 12 | 0 | 12 |
2006 | 8 | 2 | 10 |
2007 | 13 | 5 | 18 |
2008 | 16 | 3 | 19 |
2009 | 22 | 4 | 26 |
2010 | 14 | 4 | 18 |
2011 | 17 | 3 | 20 |
2012 | 6 | 7 | 13 |
2013 | 15 | 3 | 18 |
2014 | 22 | 1 | 23 |
2015 | 19 | 5 | 24 |
2016 | 14 | 1 | 15 |
2017 | 16 | 1 | 17 |
2018 | 10 | 4 | 14 |
2019 | 14 | 3 | 17 |
2020 | 21 | 1 | 22 |
2021 | 12 | 3 | 15 |
2022 | 15 | 0 | 15 |
2023 | 11 | 0 | 11 |
2024 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Osteosarcoma" by people in Profiles.
-
Identification of an early survival prognostic gene signature for localized osteosarcoma patients. Sci Rep. 2024 03 27; 14(1):7327.
-
Systemic Cisplatin Does Not Affect the Bone Regeneration Process in a Critical Size Defect Murine Model. ACS Biomater Sci Eng. 2024 Mar 11; 10(3):1646-1660.
-
Cell membrane-anchored and tumor-targeted IL-12 T-cell therapy destroys cancer-associated fibroblasts and disrupts extracellular matrix in heterogenous osteosarcoma xenograft models. J Immunother Cancer. 2024 01 09; 12(1).
-
GD2-CAR CAR T?cells in patients with osteosarcoma and neuroblastoma-it's not only the T cells that matter. Cancer Cell. 2024 01 08; 42(1):8-10.
-
The Landscape of Alterations from 1407 Ultra-Rare Sarcomas from the AACR GENIE Database: Clinical Implications. Clin Cancer Res. 2023 11 14; 29(22):4669-4678.
-
Overview of CD70 as a Potential Therapeutic Target for Osteosarcoma. J Immunol. 2023 10 01; 211(7):1067-1072.
-
The Role of FAS Receptor Methylation in Osteosarcoma Metastasis. Int J Mol Sci. 2023 Jul 29; 24(15).
-
Sodium fluoride (Na18F) PET Response Criteria in Solid Tumors (NAFCIST): a framework for response assessment in bone tumors. ESMO Open. 2023 08; 8(4):101575.
-
Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants. Cancer Res. 2023 07 14; 83(14):2297-2311.
-
Children's Oncology Group's 2023 blueprint for research: Epidemiology. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30566.